利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

212 条记录 (耗时 0.047 秒)

    Tricyclic opioid modulators
    121.
    发明授权
    Tricyclic opioid modulators 失效
    三环阿片样物质调节剂

    公开(公告)号：US07582650B2

    公开(公告)日：2009-09-01

    申请号：US11424311

    申请日：2006-06-15

    申请人： Bart DeCorte ,  Li Liu ,  Mark McDonnell ,  Jim McNally

    发明人： Bart DeCorte ,  Li Liu ,  Mark McDonnell ,  Jim McNally

    IPC分类号： C07D221/22 ,  A61K31/46

    CPC分类号： C07D451/02 ,  C07D405/04 ,  C07D451/14

    摘要： The invention is directed to compounds of Formula (I) useful as delta and mu opioid receptor modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

    摘要翻译： 本发明涉及用作δ和μ阿片样物质受体调节剂的式（I）化合物。 还描述了使用本发明的化合物治疗轻度至重度疼痛和各种疾病的药物和兽医组合物和方法。

    METHOD AND APPARATUS FOR REDUCING INTERMODULATION DISTORTION IN AN ELECTRONIC DEVICE HAVING AN AMPLIFIER CIRCUIT
    122.
    发明申请
    METHOD AND APPARATUS FOR REDUCING INTERMODULATION DISTORTION IN AN ELECTRONIC DEVICE HAVING AN AMPLIFIER CIRCUIT 有权
    用于减小具有放大器电路的电子设备中的互调失真的方法和装置

    公开(公告)号：US20090189691A1

    公开(公告)日：2009-07-30

    申请号：US12021061

    申请日：2008-01-28

    申请人： Junxiong Deng ,  Li Liu ,  Prasad S. Gudem

    发明人： Junxiong Deng ,  Li Liu ,  Prasad S. Gudem

    IPC分类号： H03F1/26

    CPC分类号： H03F3/193 ,  H03F1/223 ,  H03F1/3205 ,  H03F1/34 ,  H03F2200/294 ,  H03F2201/3206

    摘要： An electronic device includes an amplifier circuit coupled to a linearizer. The amplifier circuit may receive a first input signal including first and second frequencies and generate a first output signal including a delta frequency signal at a delta frequency, which is the difference between the first frequency and the second frequency. The linearizer includes a signal detector circuit, a current-mirror circuit, a low pass filter, a phase shifter, and a bias circuit. The signal detector circuit may generate a second output signal. The current-mirror circuit may adjust an amplitude of a signal. The low pass filter may eliminate a portion of the second output signal having frequencies greater than the delta frequency. The phase shifter may generate a feedback signal corresponding to the delta frequency signal. An amplitude and/or a phase of the feedback signal is different from an amplitude and/or a phase of the delta frequency signal.

    摘要翻译： 电子设备包括耦合到线性化器的放大器电路。 放大器电路可以接收包括第一和第二频率的第一输入信号，并产生第一输出信号，该第一输出信号包括第一频率和第二频率之间的差异的增量频率的增量频率信号。 线性化器包括信号检测器电路，电流镜电路，低通滤波器，移相器和偏置电路。 信号检测器电路可以产生第二输出信号。 电流镜电路可以调节信号的幅度。 低通滤波器可以消除具有大于Δ频率的频率的第二输出信号的一部分。 移相器可以产生对应于Δ频率信号的反馈信号。 反馈信号的幅度和/或相位与增量频率信号的振幅和/或相位不同。

    Apparatus and method for a system architecture for multiple antenna wireless communication systems using round robin channel estimation and transmit beam forming algorithms
    124.
    发明授权
    Apparatus and method for a system architecture for multiple antenna wireless communication systems using round robin channel estimation and transmit beam forming algorithms 有权
    用于使用轮询信道估计和发射波束形成算法的多天线无线通信系统的系统架构的装置和方法

    公开(公告)号：US07539458B2

    公开(公告)日：2009-05-26

    申请号：US11584831

    申请日：2006-10-23

    申请人： Hamid Jafarkhani ,  Li Liu

    发明人： Hamid Jafarkhani ,  Li Liu

    IPC分类号： H04B1/00 ,  H04B15/00

    CPC分类号： H04B7/0617 ,  H04B7/0626

    摘要： A multiple antenna wireless system including a transmitter and a receiver comprises a reconfigurable large antenna array having a plurality of antennas. A plurality of RF chains in the transmitter is coupled to the reconfigurable large antenna array. A pilot assisted round robin channel estimation means tracks the fading channel; and an adaptive round robin transmit beamforming means beam forms the reconfigurable large antenna array. A method for multiple antenna wireless communication comprising the steps of tracking a plurality of fading channels in a reconfigurable large antenna array having a plurality of antennas using pilot assisted round robin channel estimation to selectively couple a plurality of RF chains in the transmitter to the reconfigurable large antenna array, and adaptively, round-robin transmit beamforming the reconfigurable large antenna array.

    摘要翻译： 包括发射机和接收机的多天线无线系统包括具有多个天线的可重构大天线阵列。 发射机中的多个RF链耦合到可重新配置的大天线阵列。 导频辅助循环信道估计装置跟踪衰落信道; 并且自适应轮询发射波束成形装置波束形成可重构大天线阵列。 一种用于多天线无线通信的方法，包括以下步骤：使用导频辅助循环信道估计来跟踪具有多个天线的可重构大型天线阵列中的多个衰落信道，以选择性地将发射机中的多个RF链耦合到可重新配置的大的 天线阵列，以及自适应地轮循发射波束成形可重构大天线阵列。

    Normalization methods for G-protein coupled receptor membrane array
    125.
    发明申请
    Normalization methods for G-protein coupled receptor membrane array 审中-公开
    G蛋白偶联受体膜阵列的归一化方法

    公开(公告)号：US20090131263A1

    公开(公告)日：2009-05-21

    申请号：US11985990

    申请日：2007-11-19

    申请人： Longying Dong ,  Yulong Hong ,  Joydeep Lahiri ,  Fang Lai ,  Li Liu ,  Jeffrey G. Lynn

    发明人： Longying Dong ,  Yulong Hong ,  Joydeep Lahiri ,  Fang Lai ,  Li Liu ,  Jeffrey G. Lynn

    IPC分类号： C40B20/04 ,  C40B40/10 ,  C40B50/14

    CPC分类号： G01N33/554 ,  G01N2333/726 ,  G01N2500/10

    摘要： Reference membrane components are either pre-labeled or labeled during assays for purposes of normalizing signals associated with binding or functional assays employing G-protein coupled receptor microarrays. A reference component may be included in a membrane in which the target GPCR is embedded or may be present in another membrane printed in conjunction with the target membrane on a microspot. Or, a GPCR microarray may be pre-labeled by incorporating a label on an exposed substrate in a defect in the printed microspot.

    摘要翻译： 参考膜组分在测定期间被预标记或标记，目的是使与G-蛋白偶联受体微阵列的结合或功能测定相关的信号归一化。 参考组分可以包括在其中嵌入目标GPCR的膜中，或者可以存在于与微孔上的靶膜结合印刷的另一膜中。 或者，GPCR微阵列可以通过在印刷的微点的缺陷中的暴露的基底上并入标签来进行预标记。

    Method and apparatus to achieve maximum outer level parallelism of a loop
    126.
    发明申请
    Method and apparatus to achieve maximum outer level parallelism of a loop 有权
    实现环路最大外层平行度的方法和装置

    公开(公告)号：US20090064120A1

    公开(公告)日：2009-03-05

    申请号：US11897468

    申请日：2007-08-30

    申请人： Li Liu ,  Buqi Cheng ,  Gansha Wu

    发明人： Li Liu ,  Buqi Cheng ,  Gansha Wu

    IPC分类号： G06F9/45

    CPC分类号： G06F8/452

    摘要： In one embodiment, the present invention includes a method for constructing a data dependency graph (DDG) for a loop to be transformed, performing statement shifting to transform the loop into a first transformed loop according to at least one of first and second algorithms, performing unimodular and echelon transformations of a selected one of the first or second transformed loops, partitioning the selected transformed loop to obtain maximum outer level parallelism (MOLP), and partitioning the selected transformed loop into multiple sub-loops. Other embodiments are described and claimed.

    摘要翻译： 在一个实施例中，本发明包括一种用于构造要变换的循环的数据依赖图（DDG）的方法，执行语句移位以根据第一和第二算法中的至少一个将循环变换为第一变换循环，执行 对所选择的第一或第二变换循环中的一个进行单模和梯形变换，分割所选择的变换循环以获得最大外部水平并行度（MOLP），以及将所选择的变换循环分割成多个子循环。 描述和要求保护其他实施例。

    Novel polysaccharide pro-drug 5-fluorouracil (5-FU) with enhanced target specificity for colorectal cancer and its preparation methods
    129.
    发明申请
    Novel polysaccharide pro-drug 5-fluorouracil (5-FU) with enhanced target specificity for colorectal cancer and its preparation methods 审中-公开

    公开(公告)号：US20080085871A1

    公开(公告)日：2008-04-10

    申请号：US11657753

    申请日：2007-09-17

    申请人： Joemy Tam ,  Qi Mei ,  Li Liu ,  Qing Wang

    发明人： Joemy Tam ,  Qi Mei ,  Li Liu ,  Qing Wang

    IPC分类号： A61K31/7072 ,  A61P35/00 ,  C07H1/00 ,  C07H19/06 ,  C07H3/00

    CPC分类号： A61K31/716 ,  A61K47/61 ,  C08B37/0036 ,  C08B37/0045 ,  C08B37/0096

    摘要： This invention describes a novel polysaccharide prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for colorectal cancer treatment, and its preparation methods. The prodrug is synthesized by chemically linking anti-cancer drug 5-fluorouracil (5-FU) with a specially selected polysaccharide with molecular weight of 105˜107 Da containing galactose residues. Its distinctive characteristics are that it is a prodrug synthesized by chemically linking polysaccharides with 5-FU through different bridge links for the targeted treatment of colorectal cancer; that the polysaccharides in the chemical compound contain galactose residues; and that these polysaccharides are prepared from natural gums or plant materials. Due to these unique characteristics, as an oral preparation, the polysaccharide component of this novel prodrug can protect the active agent 5-FU from absorption (or metabolism) in the upper gastrointestinal tract and deliver a high concentration of the 5-FU to the colorectal area. Upon reaching the colorectal area, the 5-FU-galactose portion of the prodrug will bind to galectin-3, a-galactoside-binding protein implicated in tumor progression by interactions with its ligands, such as TF (Thomsen-Friedenreich, Galb3GalNAc), Tn (GalNAcaThr/Ser), and Sialy-Tn with galactose residues, which are highly expressed among colorectal cancer cells. Finally, the active 5-FU component will be released locally from the polysaccharide via enzymatic hydrolysis from the local bacterial flora, allowing it to actively kill the colorectal cancer cells. In summary, this novel target-specific prodrug can enhance the selectivity of 5-FU and increase its therapeutic effects in the treatment of colorectal cancer. In addition, with this enhanced target specificity, it is possible to maximize the 5-FU efficacy in cancer patients by having either less toxicity with the same or higher therapeutic dose, and/or administer a lower dosage (if so desired) to achieve the same therapeutic effects, but with much less toxicity. Multiple examples of various approaches to synthesize this novel prodrug are enclosed herein along with several animal model experiments to substantiate the claims as stated above.